news
Greenstone uses stem cells for Duchenne heart disease
Greenstone Biosciences received NIH funding to develop drugs for Duchenne muscular dystrophy (DMD) cardiomyopathy. They're using human induced pluripotent stem cells (iPSCs) and AI to find treatments, aiming to bypass the high failure rate of animal models in human trials. This could mean better drug candidates for Duchenne patients and a new approach for other heart conditions.
Greenstone Biosciences received NIH funding to develop drugs for Duchenne muscular dystrophy (DMD) cardiomyopathy. They're using human induced pluripotent stem cells (iPSCs) and AI to find treatments, aiming to bypass the high failure rate of animal models in human trials. This could mean better drug candidates for Duchenne patients and a new approach for other heart conditions.
The architecture take
I'm always skeptical of 'AI-powered' everything, but this is a real problem. Nine out of ten drugs fail moving from animal models to humans, and heart stuff is even worse. Greenstone's using human heart cells derived from iPSCs to test drugs for DMD. That's a direct route. It means they're looking at human physiology from the jump, not hoping a mouse heart translates to yours. Duchenne patients might actually get better options for their cardiomyopathy, which is often the cause of death. But the bigger play here is the model: if this works for DMD, expect to see the 'human-cells-first' approach take off for other difficult conditions. It’s a bet on biological relevance over traditional animal models, and I like that. We'll see if the funding translates into actual therapies, but the mechanism makes sense.